CellaVision AB (publ) (CLVSF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, CellaVision AB (publ) (CLVSF) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 52/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026CellaVision AB (publ) (CLVSF) Resumen de Asistencia Médica y Tuberías
CellaVision AB (publ) provides digital solutions for blood and body fluid analysis, automating and standardizing morphological examination. Serving hospitals and commercial labs globally, the company's key differentiators include its advanced cell imaging technology and comprehensive software suite, positioning it as a leader in hematology diagnostics within the medical devices sector.
Tesis de Inversión
CellaVision AB (publ) presents a notable research candidate within the medical devices sector, driven by the increasing demand for automated and standardized diagnostic solutions. The company's strong gross margin of 68.5% and profit margin of 20.2% indicate efficient operations and pricing power. Growth catalysts include the expansion of its product portfolio and penetration into new geographic markets. Key value drivers include the recurring revenue from software licenses and service contracts, as well as the potential for increased adoption of its solutions in veterinary medicine. Potential risks include competition from established players and the impact of regulatory changes on the medical devices industry. The company's P/E ratio of 23.09 suggests a premium valuation, reflecting investor expectations for future growth.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $0.38B reflects CellaVision's current valuation in the medical devices market.
- P/E Ratio of 23.09 indicates the price investors are willing to pay for each dollar of CellaVision's earnings.
- Profit Margin of 20.2% demonstrates CellaVision's ability to generate profit from its revenue.
- Gross Margin of 68.5% showcases the efficiency of CellaVision's production and pricing strategies.
- Dividend Yield of 1.69% provides investors with a return on their investment through dividend payments.
Competidores y Pares
Fortalezas
- Proprietary technology in digital cell morphology.
- Strong brand reputation and established customer base.
- High gross and profit margins.
- Comprehensive suite of hardware and software solutions.
Debilidades
- Limited geographic diversification.
- Dependence on hospital and commercial laboratories.
- Relatively small market capitalization.
- OTC market listing may limit investor access.
Catalizadores
- Ongoing: Expansion into emerging markets, driven by increasing healthcare investments in Asia Pacific and Latin America.
- Ongoing: Product portfolio diversification with new applications for hematology and diagnostics.
- Upcoming: Potential strategic partnerships or acquisitions to expand market reach and capabilities.
- Ongoing: Increased adoption of CellaVision VET solutions in the growing veterinary medicine market.
- Ongoing: Development and integration of AI-powered diagnostic tools for improved accuracy and efficiency.
Riesgos
- Potential: Increased competition from established medical device companies with greater resources.
- Potential: Regulatory changes in the healthcare industry affecting product approvals and reimbursement.
- Potential: Economic downturns impacting hospital budgets and capital expenditures.
- Potential: Technological obsolescence requiring continuous innovation and product development.
- Ongoing: Risks associated with OTC market listing, including limited liquidity and disclosure.
Oportunidades de crecimiento
- Expansion into Emerging Markets: CellaVision has the opportunity to expand its presence in emerging markets, such as Asia Pacific and Latin America, where healthcare infrastructure is rapidly developing and the demand for advanced diagnostic solutions is increasing. These markets offer significant growth potential due to their large populations and unmet medical needs. Successful penetration into these regions could substantially increase CellaVision's revenue and market share over the next 3-5 years.
- Product Portfolio Diversification: CellaVision can diversify its product portfolio by developing new applications and solutions for different areas of hematology and diagnostics. This could include expanding into molecular diagnostics or developing specialized solutions for specific diseases. By broadening its product offerings, CellaVision can attract new customers and increase its revenue per customer, driving long-term growth.
- Strategic Partnerships and Acquisitions: CellaVision can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. Collaborating with other companies in the medical devices or diagnostics industry can provide access to new technologies, markets, and customers. Acquisitions can also be used to consolidate the market and eliminate competition, creating a stronger and more dominant player.
- Increased Adoption in Veterinary Medicine: CellaVision's VET solution offers a significant growth opportunity in the veterinary medicine market. As pet ownership continues to rise and veterinary practices become more sophisticated, the demand for advanced diagnostic solutions in veterinary care is increasing. By focusing on this market, CellaVision can leverage its existing technology and expertise to capture a growing share of the veterinary diagnostics market.
- Development of AI-Powered Diagnostic Tools: CellaVision can leverage artificial intelligence (AI) to develop new diagnostic tools that improve the accuracy and efficiency of cell morphology analysis. AI-powered solutions can automate the identification and classification of cells, reducing the workload for laboratory technicians and improving diagnostic accuracy. This can lead to increased adoption of CellaVision's solutions and a competitive advantage in the market.
Oportunidades
- Expansion into emerging markets.
- Product portfolio diversification.
- Increased adoption in veterinary medicine.
- Development of AI-powered diagnostic tools.
Amenazas
- Competition from established medical device companies.
- Regulatory changes in the healthcare industry.
- Economic downturns affecting hospital budgets.
- Technological obsolescence.
Ventajas competitivas
- Proprietary technology in digital cell morphology analysis.
- Established customer base in hospitals and commercial laboratories.
- Integrated hardware and software solutions.
- Strong brand reputation for accuracy and reliability.
Acerca de CLVSF
CellaVision AB (publ), founded in 1994 and headquartered in Lund, Sweden, develops and markets digital solutions for blood and body fluid analysis. The company's core products include the CellaVision DM1200, DM9600, and DC-1 analyzers, which automatically capture digital images of cells from blood smears and body fluid preparations. These analyzers are complemented by a suite of software applications, such as the CellaVision Peripheral Blood Application, Advanced RBC Application, Body Fluid Application, and Remote Review Software, designed to automate, standardize, and simplify morphological examination. CellaVision's solutions cater to hospital and commercial laboratories, enabling them to streamline workflows, improve accuracy, and enhance efficiency in hematology diagnostics. The company's geographic reach extends across Europe, the Middle East, Africa, the Americas, and the Asia Pacific. CellaVision differentiates itself through its integrated hardware and software approach, offering a comprehensive solution for digital cell morphology. This positions them competitively against other players in the medical devices market, particularly those focused on laboratory automation and diagnostics.
Qué hacen
- Develops and sells digital imaging solutions for blood and body fluid analysis.
- Offers automated cell morphology analyzers for hospital and commercial laboratories.
- Provides software applications for streamlining and standardizing diagnostic workflows.
- Enables remote review of blood smears and body fluid preparations.
- Offers solutions for both human and veterinary hematology.
- Provides tools for assessing and monitoring staff competency in cell morphology.
Modelo de Negocio
- Sells automated cell morphology analyzers (CellaVision DM1200, DM9600, DC-1) to hospitals and commercial labs.
- Generates recurring revenue through software licenses and service contracts.
- Offers cloud-based software solutions for proficiency testing and education.
- Provides digital solutions for medical microscopy in veterinary hematology.
Contexto de la Industria
CellaVision AB (publ) operates within the medical devices industry, specifically focusing on in-vitro diagnostics and laboratory automation. The industry is characterized by technological advancements, increasing regulatory scrutiny, and growing demand for accurate and efficient diagnostic solutions. The global in-vitro diagnostics market is projected to reach $100 billion by 2028, driven by the rising prevalence of chronic diseases and the increasing adoption of point-of-care testing. CellaVision competes with other medical device manufacturers and diagnostic companies, including AVNBF (Avon Rubber P.L.C.) and BJTRF (Bio-Rad Laboratories, Inc.), in a fragmented market landscape.
Clientes Clave
- Hospital laboratories
- Commercial laboratories
- Veterinary clinics and hospitals
- Research institutions
Finanzas
Gráfico e información
Precio de la acción de CellaVision AB (publ) (CLVSF): Price data unavailable
Últimas noticias
-
3 Undervalued European Small Caps With Insider Buying
Simply Wall St. · 16 feb 2026
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CLVSF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para CLVSF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CLVSF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Simon Ostergaard
CEO
Simon Ostergaard serves as the CEO of CellaVision AB (publ). Information regarding his detailed career history and educational background is not available in the provided data. As CEO, he is responsible for leading the company's strategic direction, overseeing operations, and driving growth in the global market for digital cell morphology solutions. His leadership is crucial for CellaVision's continued success and innovation in the healthcare sector.
Historial: Specific achievements and milestones under Simon Ostergaard's leadership are not detailed in the provided data. However, as CEO, he is responsible for overseeing the company's financial performance, product development, and market expansion. His strategic decisions and leadership play a critical role in shaping CellaVision's future growth and competitive positioning.
Información del mercado OTC de CLVSF
The OTC Other tier represents the lowest tier of the OTC market, indicating that CellaVision AB (publ) may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and regulatory oversight compared to those listed on major exchanges like the NYSE or NASDAQ. This can result in higher risks for investors due to the potential for less transparency and greater information asymmetry.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and regulatory oversight.
- Lower trading volume and liquidity.
- Wider bid-ask spreads.
- Potential for price manipulation and fraud.
- Higher information asymmetry.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investing.
- Established business operations in the healthcare sector.
- Proprietary technology in digital cell morphology analysis.
- Customer base of hospitals and commercial laboratories.
- Presence in multiple geographic markets (Europe, Americas, Asia Pacific).
- Positive gross and profit margins.
CLVSF Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar CLVSF?
CellaVision AB (publ) (CLVSF) actualmente tiene una puntuación IA de 52/100, indicando puntuación moderada. Fortaleza clave: Proprietary technology in digital cell morphology.. Riesgo principal a monitorear: Potential: Increased competition from established medical device companies with greater resources.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CLVSF?
CLVSF actualmente puntúa 52/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CLVSF?
Los precios de CLVSF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CLVSF?
La cobertura de analistas para CLVSF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CLVSF?
Las categorías de riesgo para CLVSF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Increased competition from established medical device companies with greater resources.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CLVSF?
La relación P/E para CLVSF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CLVSF sobrevalorada o infravalorada?
Determinar si CellaVision AB (publ) (CLVSF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CLVSF?
CellaVision AB (publ) (CLVSF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.